Recombinant BCG Immunotherapy for BCG-Refractory Non–Muscle-Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
Eur Urol Oncol 2022 Jan 07;[EPub Ahead of Print], CA Rentsch, GN Thalmann, I Lucca, M Kwiatkowski, GJ Wirth, RT Strebel, D Engeler, A Pedrazzini, C Hüttenbrink, W Schultze-Seemann, R Torpai, L Bubendorf, A Wicki, B Roth, P Bosshard, H Püschel, DT Boll, L Hefermehl, F Roghmann, M Gierth, K Ribi, S Schäfer, S HayozFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.